Related Experiment Video
Updated: May 27, 2026

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled,
Andreas W Schoenenberger1, Renate Schoenenberger-Berzins, Christoph Auf der Maur
1Division of Geriatrics, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Background:
Diuretic treatment for heart failure may lead to an increased urinary thiamine excretion and in long-term thiamine deficiency, which may further compromise cardiac function. This study evaluated the effect of high dose thiamine supplementation in heart failure patients.
Methods:
Nine patients with diuretic treatment for symptomatic chronic heart failure and a left ventricular ejection fraction (LVEF) <40% were randomly assigned to receive thiamine (300 mg/day) or placebo for 28 days. After a wash-out of 6 weeks, the patients crossed-over to a second treatment period. The primary outcome was a change in LVEF.
Results:
Mean age was 56.7 ± 9.2 years (range 44.9-75.4 years). Baseline LVEF was similar for both treatment groups (29.5% in the thiamine group and 29.5% in the placebo group, P = 0.911). After 28 days of thiamine treatment, the LVEF increased to 32.8% which was significantly (P = 0.024) different from the LVEF in the placebo group (28.8%). This corresponds to a treatment effect for LVEF of 3.9% in absolute terms.
Conclusions:
This study suggests that thiamine supplementation has beneficial effects on cardiac function in patients with diuretic drugs for symptomatic chronic heart failure. Subclinical thiamine deficiency is probably an underestimated issue in these outpatients.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Heart Failure III: Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Heart Failure Drugs: Inotropic Agents
